Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Neurocrine Biosciences (NBIX) EPS (Weighted Average and Diluted): 2010-2021

Historic EPS (Weighted Average and Diluted) for Neurocrine Biosciences (NBIX) over the last 9 years, with Sep 2021 value amounting to $0.23.

  • Neurocrine Biosciences' EPS (Weighted Average and Diluted) rose 137.10% to $0.23 in Q3 2021 from the same period last year, while for Sep 2021 it was $4.57, marking a year-over-year increase of 391.40%. This contributed to the annual value of $4.16 for FY2020, which is 966.67% up from last year.
  • Per Neurocrine Biosciences' latest filing, its EPS (Weighted Average and Diluted) stood at $0.23 for Q3 2021, which was down 46.51% from $0.43 recorded in Q2 2021.
  • In the past 5 years, Neurocrine Biosciences' EPS (Weighted Average and Diluted) ranged from a high of $3.58 in Q4 2020 and a low of -$1.12 during Q1 2019.
  • Over the past 3 years, Neurocrine Biosciences' median EPS (Weighted Average and Diluted) value was $0.39 (recorded in 2020), while the average stood at $0.50.
  • Data for Neurocrine Biosciences' EPS (Weighted Average and Diluted) shows a peak YoY increase of 922.86% (in 2020) and a maximum YoY decrease of 210.71% (in 2020) over the last 5 years.
  • Over the past 5 years, Neurocrine Biosciences' EPS (Weighted Average and Diluted) (Quarterly) stood at $0.07 in 2017, then surged by 171.43% to $0.19 in 2018, then soared by 84.21% to $0.35 in 2019, then skyrocketed by 922.86% to $3.58 in 2020, then soared by 137.10% to $0.23 in 2021.
  • Its EPS (Weighted Average and Diluted) was $0.23 in Q3 2021, compared to $0.43 in Q2 2021 and $0.33 in Q1 2021.